A Phase II Trial Of Bryostatin-1 In Combination With Rituximab In Rituximab-Refractory Indolent B-Cell Non Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Bryostatin-1; Rituximab
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 30 Apr 2015 Biomarkers information updated
- 19 Feb 2012 Additional lead trial investigator (Espinoza-Delgado I) identified as reported by ClinicalTrials.gov.
- 06 Nov 2007 Status change from recruiting to completed.